Guardant Health, Inc. $GH Shares Sold by Entropy Technologies LP

Entropy Technologies LP trimmed its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 64.1% in the 1st quarter, Holdings Channel.com reports. The firm owned 6,136 shares of the company’s stock after selling 10,957 shares during the period. Entropy Technologies LP’s holdings in Guardant Health were worth $567,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. V Square Quantitative Management LLC purchased a new stake in Guardant Health during the fourth quarter worth $27,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Guardant Health during the fourth quarter valued at $31,000. Elyxium Wealth LLC purchased a new position in Guardant Health in the fourth quarter valued at $35,000. Parallel Advisors LLC increased its holdings in Guardant Health by 164.7% in the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after buying an additional 219 shares in the last quarter. Finally, Ascentis Independent Advisors acquired a new position in shares of Guardant Health in the first quarter worth about $38,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Helmy Eltoukhy sold 100,000 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $126.30, for a total transaction of $12,630,000.00. Following the completion of the transaction, the chief executive officer owned 2,012,919 shares in the company, valued at $254,231,669.70. This represents a 4.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Myrtle S. Potter sold 1,556 shares of the company’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $131.16, for a total transaction of $204,084.96. Following the transaction, the director owned 20,971 shares of the company’s stock, valued at approximately $2,750,556.36. This trade represents a 6.91% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 708,565 shares of company stock valued at $90,556,597. 5.60% of the stock is owned by company insiders.

Guardant Health Stock Performance

Shares of NASDAQ GH opened at $144.23 on Thursday. The firm has a fifty day moving average of $141.90 and a 200 day moving average of $112.74. The firm has a market cap of $19.12 billion, a PE ratio of -42.55 and a beta of 1.59. Guardant Health, Inc. has a one year low of $40.35 and a one year high of $174.08.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Wolfe Research assumed coverage on shares of Guardant Health in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 target price on the stock. Barclays lifted their price target on Guardant Health from $120.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, June 24th. Citigroup upped their price target on Guardant Health from $150.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Bank of America upped their price target on Guardant Health from $135.00 to $190.00 and gave the stock a “buy” rating in a report on Monday, July 6th. Finally, TD Cowen reiterated a “buy” rating on shares of Guardant Health in a research report on Thursday, July 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Guardant Health presently has a consensus rating of “Moderate Buy” and an average price target of $160.04.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.